Mylan CEO Heather Bresch continues to defend the high cost of EpiPens by pointing out that middlemen in the drug’s supply chain take 55 percent of the medication’s list price, according to Health ...

Mylan has launched a biosimilar version of Sanofi’s best-selling insulin, Lantus, that it says is priced 65 percent lower than comparable insulins. The biosimilar, called Semglee, costs $147.98 for a ...

Mylan and Pfizer have spent years defending their marketing of the popular epinephrine injector EpiPen. After a busy couple of months in court, the partners have now wiped their hands of another ...

Mylan N.V. MYL and its India-based partner Biocon announced that the FDA has approved their biosimilar version of Roche’s RHHBY Herceptin (trastuzumab). The biosimilar will be available under the ...

Pharmacy Benefit Managers Shouldn't Fret Initial Fallout from Mylan Fiasco Mylan pushed the blame for high EpiPen prices onto PBMs Thursday, causing share prices to dip. Analysts say investors were ...

Mylan Pharmaceuticals is pulling a batch of Xanax from pharmacy shelves nationwide because of what the company said is "the potential presence of a foreign substance" in the popular prescription ...

Mylan’s announcement of its expanded patient-assistance program drips with cynicism. In its news release, Bresch states: “We recognize the significant burden on patients from continued, rising ...

PITTSBURGH — Generic drug maker Mylan has bought rights to a drug delivery platform made by Pfizer that will allow it to make generic versions of two GlaxoSmithKline respiratory drugs, Mylan said ...

Drugmaker Mylan said Monday that it will offer a generic version of the life-saving allergy treatment EpiPen for half the list price of the brand-name treatment after it became the center of a ...

Mylan CEO Heather Bresch faced brutal questioning spanning over six hours Wednesday from members of the House Committee on Oversight and Government Reform, which convened to investigate the company's ...